Imipenem versus piperacillin/tazobactam for empiric treatment of neutropenic fever in adults

被引：11

作者：

Roohullah, A. ^{[1
]}

Moniwa, A. ^{[1
]}

Wood, C. ^{[1
,2
]}

Humble, M. ^{[3
,4
]}

Balm, M. ^{[4
]}

Carter, J. ^{[1
,3
]}

Weinkove, R. ^{[1
,3
]}

机构：

[1] Capital & Coast Dist Hlth Board, Wellington Blood & Canc Ctr, Wellington 6242, New Zealand

[2] Univ Otago Wellington, Malaghan Inst Med Res, Wellington, New Zealand

[3] Univ Otago Wellington, Dept Pathol & Mol Med, Wellington, New Zealand

[4] Capital & Coast Dist Hlth Board, Microbiol Lab, Wellington 6242, New Zealand

来源：

INTERNAL MEDICINE JOURNAL | 2013年 / 43卷 / 10期

关键词：

neutropenia; sepsis; imipenem; piperacillin; tazobactam; FEBRILE NEUTROPENIA; CANCER-PATIENTS; ANTIMICROBIAL THERAPY; TAZOBACTAM; CHEMOTHERAPY; MONOTHERAPY; GUIDELINES; MANAGEMENT; CEFEPIME; SOCIETY;

D O I：

10.1111/imj.12226

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Australian guidelines for neutropenic fever recommend piperacillin/tazobactam (PIP-TAZ) or cefepime for first-line empiric treatment of neutropenic fever. We compared outcomes among haematology patients before and after changing our first-line neutropenic fever treatment from imipenem to PIP-TAZ. Forty-five patients received imipenem and 60 PIP-TAZ. Despite a higher rate of antibiotic modification in the PIP-TAZ cohort, treatment success and time to defervescence were similar, with a trend towards fewer Clostridium difficile infections in the PIP-TAZ cohort.

引用

页码：1151 / 1154

页数：4

共 17 条

[1] A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with Hematologic malignancies [J].

Bow, E. J. ;

Rotstein, C. ;

Noskin, G. A. ;

Laverdiere, M. ;

Schwarer, A. P. ;

Segal, B. H. ;

Seymour, J. F. ;

Szer, J. ;

Sanche, S. .

CLINICAL INFECTIOUS DISEASES, 2006, 43 (04) :447-459

[2] First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study [J].

Brack, Eva ;

Bodmer, Nicole ;

Simon, Arne ;

Leibundgut, Kurt ;

Kuehne, Thomas ;

Niggli, Felix K. ;

Ammann, Roland A. .

PEDIATRIC BLOOD & CANCER, 2012, 59 (03) :423-430

[3]

Chandrasekar PH, 2000, ANN PHARMACOTHER, V34, P989

[4] Management of febrile neutropenia: ESMO Clinical Practice Guidelines [J].

de Naurois, J. ;

Novitzky-Basso, I. ;

Gill, M. J. ;

Marti, F. Marti ;

Cullen, M. H. ;

Roila, F. .

ANNALS OF ONCOLOGY, 2010, 21 :v252-v256

[5] Initial empiric therapy of febrile neutropenia with antibiotic monotherapy.: Piperacillin/tazobactam versus imipenem/cilastatin (1994-1996) [J].

Figuera, R ;

Rivero, N ;

Pajuelo, F ;

Font, P ;

Leyra, F ;

de la Cámara, R ;

Arranz, R ;

Rañada, JMF .

MEDICINA CLINICA, 2001, 116 (16) :610-611

[6]

Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073

[7] The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients [J].

Klastersky, J ;

Paesmans, M ;

Rubenstein, EB ;

Boyer, M ;

Elting, L ;

Feld, R ;

Gallagher, J ;

Herrstedt, J ;

Rapoport, B ;

Rolston, K ;

Talcott, J .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :3038-3051

[8] Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients [J].

Kuderer, NM ;

Dale, DC ;

Crawford, J ;

Cosler, LE ;

Lyman, GH .

CANCER, 2006, 106 (10) :2258-2266

[9] Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy [J].

Lyman, GH ;

Morrison, VA ;

Dale, DC ;

Crawford, J ;

Delgado, DJ ;

Fridman, M .

LEUKEMIA & LYMPHOMA, 2003, 44 (12) :2069-2076

[10]

National Comprehensive Cancer Network, 2013, PREV TREATM CANC REL

← 1 2 →